(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
Live Chart Being Loaded With Signals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides...
Stats | |
---|---|
Today's Volume | 76 324.00 |
Average Volume | 145 014 |
Market Cap | 97.04M |
EPS | $0 ( 2024-05-09 ) |
Next earnings date | ( $0 ) 2024-07-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 17.11 |
ATR14 | $0.00600 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Reznick Yehuda | Buy | 29 800 | Common Stock |
2024-04-01 | Reznick Yehuda | Buy | 0 | |
2024-01-30 | Aghion Daniel | Buy | 3 750 | Common Stock |
2024-01-04 | Kidron Miriam | Buy | 295 500 | Common Stock |
2024-01-04 | Kidron Nadav | Buy | 329 000 | Common Stock |
INSIDER POWER |
---|
93.06 |
Last 95 transactions |
Buy: 3 987 636 | Sell: 392 701 |
Volume Correlation
Oramed Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
PCVX | 0.883 |
BNIXU | 0.867 |
FAT | 0.849 |
SRTS | 0.843 |
LXRX | 0.839 |
MORF | 0.837 |
ADVM | 0.829 |
REE | 0.828 |
RGEN | 0.822 |
MYGN | 0.822 |
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oramed Pharmaceuticals Correlation - Currency/Commodity
Oramed Pharmaceuticals Financials
Annual | 2022 |
Revenue: | $2.70M |
Gross Profit: | $2.70M (100.00 %) |
EPS: | $-0.970 |
FY | 2022 |
Revenue: | $2.70M |
Gross Profit: | $2.70M (100.00 %) |
EPS: | $-0.970 |
FY | 2021 |
Revenue: | $2.70M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.780 |
FY | 2020 |
Revenue: | $2.71M |
Gross Profit: | $2.71M (100.00 %) |
EPS: | $-0.560 |
Financial Reports:
No articles found.
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators